Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

Study ID
NCT02047513

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

NEONAX

Trial Summary

NEONAX is an interventional, prospective, randomized, controlled, open label, two sided survival phase II studies against a fixed survival probability, with an unconnected analysis of the results in both experimental arms. Determining the impact of 2 cycles of Perioperative nab-paclitaxel/gemcitabine followed by surgery and 4 cycles of adjuvant nab-paclitaxel/gemcitabine or 6 cycles of adjuvant nab-paclitaxel/gemcitabine on the Disease free survival (DFS) rate at 18 months post randomization

More informations

Trial Starting Date

Jul 31,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

127